Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5576381 | 0.99 | SIGMAR1 (0.48) | SIGMAR1TMEM97KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL5577118 | 0.94 | SIGMAR1 (0.52) | SIGMAR1TMEM97KDM4EALDH1A1MEN1 | |
| SCHEMBL5576540 | 0.76 | ALDH1A1 (0.35) | KDM4EALDH1A1TSHRTP53SMN1; SMN2 | |
| SCHEMBL5576892 | 0.75 | PDE3B (0.39) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5577102 | 0.74 | HTR4 (0.46) | KDM4EALDH1A1ATMHSD17B10MEN1 | |
| SCHEMBL5576633 | 0.72 | CCR2 (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL11639395 | 0.69 | ALDH1A1 (0.61) | SIGMAR1TMEM97ALDH1A1HPGDMEN1 | |
| SCHEMBL17372639 | 0.66 | SIGMAR1 (1.00) | SIGMAR1TMEM97MEN1KMT2A | |
| SCHEMBL11473004 | 0.66 | DRD4 (0.65) | SIGMAR1TMEM97ALDH1A1RAB9A | |
| SCHEMBL11455234 | 0.66 | SIGMAR1 (0.60) | SIGMAR1TMEM97MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | claimed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | SIGMAR1 24/4885TMEM97 678/4885KDM4E 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.